Memantine Dosing in Dialysis Patients with Dementia
For patients on chronic dialysis with dementia, reduce memantine to a target dose of 5 mg twice daily (10 mg total daily dose). This represents a 50% reduction from the standard 20 mg daily dose used in patients with normal renal function.
Dosing Algorithm Based on Renal Function
The FDA label provides explicit guidance for renal impairment 1:
- Normal renal function (CrCl >80 mL/min): Standard dose of 10 mg twice daily (20 mg/day)
- Mild renal impairment (CrCl 50-80 mL/min): No adjustment needed; use 10 mg twice daily
- Moderate renal impairment (CrCl 30-49 mL/min): No adjustment needed; use 10 mg twice daily
- Severe renal impairment (CrCl 5-29 mL/min): Reduce to 5 mg twice daily (10 mg/day)
Patients on chronic dialysis fall into the severe renal impairment category and require dose reduction to 5 mg twice daily.
Pharmacokinetic Rationale
The dose reduction is based on solid pharmacokinetic evidence. Memantine is eliminated almost exclusively by the kidneys 2, 3. In patients with severe renal impairment (CrCl 5-29 mL/min):
- Area under the curve (AUC) increases by 115% compared to normal renal function 2
- Plasma elimination half-life extends from 61 hours to 124 hours 3
- Urinary recovery of unchanged drug decreases from 34% to only 16% 3
Simulations demonstrate that the reduced dose of 5 mg twice daily in severe renal impairment produces steady-state plasma concentrations (84 ng/mL) comparable to those achieved with 10 mg twice daily in patients with normal renal function (82 ng/mL) 2. This maintains therapeutic efficacy while avoiding drug accumulation and potential toxicity.
Titration Schedule for Dialysis Patients
Start low and titrate slowly 1:
- Week 1: 5 mg once daily
- Week 2: 5 mg twice daily (target maintenance dose)
Do not exceed 5 mg twice daily in dialysis patients. The standard titration to 20 mg/day used in patients with normal renal function is inappropriate and risks toxicity.
Timing Relative to Dialysis
While the FDA label doesn't specify timing relative to dialysis sessions, general principles for renally-cleared medications suggest administering memantine after dialysis on dialysis days 1. This approach:
- Facilitates directly observed therapy
- Prevents premature drug removal during the dialysis session
- Maintains more consistent plasma levels
Clinical Efficacy Considerations
The evidence for memantine efficacy comes primarily from patients with moderate-to-severe Alzheimer's disease 4, 5. High-certainty evidence shows small but consistent benefits in:
- Cognitive function: 3.11 SIB points improvement
- Activities of daily living: 1.09 ADL19 points improvement
- Behavioral symptoms: 1.84 NPI points improvement
However, there is no evidence that memantine benefits patients with mild dementia 4. The 2020 Canadian Consensus Conference explicitly recommends deprescribing memantine in patients with mild cognitive impairment 6.
Safety Profile in Renal Impairment
Memantine is generally well-tolerated even in severe renal impairment when appropriately dose-adjusted 1:
- Most common adverse effects: Dizziness (6.1%), headache (5.5%), confusion, constipation
- No increased risk of falls, serious adverse events, or mortality compared to placebo
- Discontinuation rates similar to placebo (10.1% vs 11.5%)
The dose reduction to 5 mg twice daily in severe renal impairment is specifically designed to maintain this favorable safety profile while preventing drug accumulation 2.
Critical Pitfalls to Avoid
Do not use standard 20 mg/day dosing in dialysis patients - this will result in drug accumulation and increased risk of adverse effects including confusion and dizziness 2, 3
Do not rely on serum creatinine alone - calculate creatinine clearance using Cockcroft-Gault equation, as serum creatinine may appear falsely normal in elderly patients with reduced muscle mass 7
Avoid alkalinizing agents - conditions that raise urine pH (carbonic anhydrase inhibitors, sodium bicarbonate) can reduce memantine clearance by 80% and cause further drug accumulation 1
Reassess appropriateness - if the patient has only mild dementia or shows no clinical benefit after 6-12 months, consider discontinuation rather than indefinite continuation 6, 8